| Target Price | ¥2,397.00 |
| Price | ¥2,318.00 |
| Potential |
3.41%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Sumitomo Dainippon Pharma 2027 .
The average Sumitomo Dainippon Pharma target price is ¥2,397.00.
This is
3.41%
register free of charge
¥2,835.00
22.30%
register free of charge
¥1,535.20
33.77%
register free of charge
|
|
| A rating was issued by 11 analysts: 6 Analysts recommend Sumitomo Dainippon Pharma to buy, 3 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sumitomo Dainippon Pharma stock has an average upside potential 2027 of
3.41%
register free of charge
|
| Mar '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion ¥ | 398.83 | 436.56 |
| 26.79% | 9.46% | |
| EBITDA Margin | 9.70% | 29.24% |
| 121.51% | 201.30% | |
| Net Margin | 5.93% | 20.55% |
| 105.92% | 246.79% |
7 Analysts have issued a sales forecast Sumitomo Dainippon Pharma 2026 . The average Sumitomo Dainippon Pharma sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Sumitomo Dainippon Pharma EBITDA forecast 2026. The average Sumitomo Dainippon Pharma EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Sumitomo Dainippon Pharma Analysts have issued a net profit forecast 2026. The average Sumitomo Dainippon Pharma net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Mar '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share ¥ | 59.49 | 225.79 |
| 107.50% | 279.54% | |
| P/E | 10.27 | |
| EV/Sales | 2.60 |
7 Analysts have issued a Sumitomo Dainippon Pharma forecast for earnings per share. The average Sumitomo Dainippon Pharma EPS is
This results in the following potential growth metrics and future valuations:
Sumitomo Dainippon Pharma...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


